XVIVO expands the US study with another leading transplant center

Barnes Jewish Hospital in St Louis, who pioneered lung transplantation, is the tenth transplant center to participate in the NOVEL trial. The Organ Procurement Organization (OPO) Mid-America Transplant Services has invested in an XPS in order to strengthen the collaboration between transplant centers and OPO's. This collaboration is the second of its kind in the USA.

Mid-American Transplant Services invested in an XPS™ and is collaborating with Barnes-Jewish Hospital in order to increase the utilization of lungs and enable transplants to more patients with severe lung disease. In 1988, Barnes-Jewish Hospital became one of the first hospitals in the United States with a program fully dedicated to lung transplantation surgery. The lung transplant program is one of the world's largest with more than 1,000 adult transplant surgeries performed.

The NOVEL trial was designed to safely increase the percentage of usable lungs from the donor pool. It is being performed at 10 centers in the United States. In the study, clinical outcomes after transplantation of lungs that have undergone warm perfusion after having been initially discarded are compared with a control group of lungs - non marginal - consisting of lungs that were initially assessed as non-transplantable. The results of the study indicate that lungs evaluated using STEEN Solution™ in an XPS™ do not differ in terms of safety and function from lungs transplanted directly. These results are consistent with those published from centers in Canada and Europe that have used STEEN Solution™ clinically and an equivalent technique.

“We are pleased that another well-known center has joined the NOVEL trial and that the connected OPO has invested in a XPS™. This collaboration is second of its kind in the US and will increase the utilization of lungs and give transplants to more patients with severe lung disease " says Dr. Magnus Nilsson CEO of XVIVO Perfusion.

January 29, 2014
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

XVIVO Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Januray 29, 2014 at 2:00 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com